Miami, FLNCT07594015Now EnrollingIRB Ready

Recurrent Endometrial Cancer Clinical Trial in Miami, FL

Access cutting-edge recurrent endometrial cancer treatment through this clinical trial at a research site in Miami. Study-provided care at no cost to qualified participants.

Sponsored by University of Miami

Quick Self-Assessment

See if you qualify for this Miami location

Preparing your pre-screening questions…

Expert Care in Miami

Access recurrent endometrial cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related recurrent endometrial cancer treatment provided free

Apply for This Miami Location

Check if you qualify for this recurrent endometrial cancer clinical trial in Miami, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Miami

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Miami site if eligible
  4. 4Begin participation

About This Recurrent Endometrial Cancer Study in Miami

The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.

Sponsor: University of Miami

Who Can Participate

Inclusion Criteria

Histologically confirmed recurrent endometrial carcinoma, including serous, endometrioid, carcinosarcoma, clear cell subtypes, with measurable disease per RECIST 1.1 criteria.
Mismatch repair (MMR) proficient status confirmed by IHC (Immunohistochemistry) or molecular testing.
Patients must have failed first-line therapy with platinum based doublet with prior immunotherapy.
Patient must have completed next-generation sequencing on either primary or recurrent tumor.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.
Age ≥ 18 years.
Female participants must be of non-childbearing potential or for females of child bearing potential (FOCBPs), must agree to use contraception as described in Section 5.6. FOCBPs must not be pregnant or breastfeeding.
At least one measurable lesion according to RECIST 1.1.
Adequate organ function, including:
Hemoglobin ≥ 8 g/dL (blood transfusions are permitted)
Absolute neutrophil count ≥ 1000
Platelet count ≥ 100 x 10⁹/L
Glomerular filtration rate (GFR) ≥ 30 mL/min
Bilirubin ≤ 1.5 x ULN (upper limit of normal)
Written informed consent obtained from the patient.
At least 3 weeks must have elapsed from any prior therapy

Exclusion Criteria

Uterine sarcoma
Active central nervous system metastases or leptomeningeal disease.
History of severe allergic reactions to pembrolizumab, lenvatinib, or any components of the formulations.
Active autoimmune disease requiring chronic systemic steroids for \> 3 months in the last 6 months prior to enrollment.
Pregnancy or breastfeeding at the time of enrollment.
Previous treatment with lenvatinib or other VEGFR inhibitors.
Concurrent treatment with other investigational drugs or anti-cancer therapies except for adjuvant hormonal therapy for breast cancer.
Uncontrolled concurrent illness, such as active infections that could interfere with study participation.
Blood pressure \>160 systolic or \>110 diastolic averaged over last 3 documented measurements.
History of significant cardiovascular events within 12 months prior to enrollment, including myocardial infarction, unstable angina, or congestive heart failure (NYHA Class III or IV).
History of organ transplant or immune suppressive therapy that would interfere with the efficacy or safety of the investigational drugs.
Other malignancies within the past 2 years except for non-melanoma skin cancer.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Miami?

Yes, this clinical trial (NCT07594015) has an active research site in Miami, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Recurrent Endometrial Cancer Treatment Options in Miami, FL

If you're searching for recurrent endometrial cancer treatment options in Miami, FL, this clinical trial (NCT07594015) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Miami research site is actively enrolling participants for this clinical trial. You'll receive care from experienced recurrent endometrial cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all recurrent endometrial cancer clinical trials near you to find additional studies recruiting in your area.

More Endometrial Cancer Trials in Miami, FL

See all endometrial cancer clinical trials recruiting in Miami — not just this study.

Browse Endometrial Cancer Trials in Miami →

Browse More Trials by Condition

Endometrial Cancer TrialsEssential Tremor TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Miami?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Miami, FL